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journal homepage: www.e lsev ier .com/ locate /yse izIn [3_TD$DIFF] ig. 1 of the above listed article, asterisks (indicating a
signiﬁcant difference [4_TD$DIFF]vs. placebo) were inadvertently omitted for
the 150 mg/day pregabalin dose. The corrected ﬁgure has these
asterisks replaced. The p-value included on the ﬁgure was also
corrected (from p [5_TD$DIFF]< 0.0001 to p  0.001).
In addition, the ﬁgure legend and the Results text report the
incorrect p-value which appeared on the original ﬁgure. Please
note the corrections below:
Original text: In the pooled data analysis, signiﬁcant reduc-
tions in seizure frequency were demonstrated for all pregabalin
doses studied vs. placebo (Fig. 1), with a positive linear dose–DOI of original article: 10.1016/j.seizure.2008.09.004
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doi:10.1016/j.seizure.2009.09.009response relationship (p < 0.0001; based on the main ANOVA
model).
Corrected text: In the pooled data analysis, signiﬁcant
reductions in seizure frequency were demonstrated for all
pregabalin doses studied vs. placebo (Fig. 1), with a positive linear
dose–response relationship (p  0.001; based on the main ANOVA
model).
Original legend: Fig. 1. Percentages reduction in seizure
frequency across all treatment groups; *p < 0.0001 vs. placebo.
Corrected legend: Fig. 1. Percentages reduction in seizure
frequency across all treatment groups; **p  0.001 vs. placebo.vier Ltd. All rights reserved.
